Royal Bank Of Canada Pharma Cyte Biotech, Inc. Transaction History
Royal Bank Of Canada
- $479 Billion
- Q4 2024
A detailed history of Royal Bank Of Canada transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 98 shares of PMCB stock, worth $174. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98
Previous 100
2.0%
Holding current value
$174
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PMCB
# of Institutions
28Shares Held
706KCall Options Held
9.3KPut Options Held
4.6K-
Vanguard Group Inc Valley Forge, PA192KShares$342,4480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA165KShares$293,2300.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$163,9147.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$147,2540.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.3KShares$87,7540.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $36.9M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...